Patient-reported outcomes with atezolizumab plus bevacizumab in metastatic kidney cancer

This study describes patient-reported outcomes from the phase 3 IMmotion151 study to assess the safety and efficacy of atezolizumab in combination with bevacizumab in patients with untreated metastatic renal cell carcinoma (RCC) and who were positive for the PD-L1 biomarker. In this study, the patients treated with atezolizumab plus bevacizumab had longer progression-free survival compared […]

read more

Atezolizumab alone or in combination with bevacizumab for untreated metastatic kidney cancer

This paper reports patient-reported outcomes from the phase 2 IMmotion150 study to assess the safety and efficacy of atezolizumab alone or in combination with bevacizumab versus sunitinib in 305 untreated metastatic renal cell carcinoma (RCC) patients. For all patients in the study, objective response rates were 25%, 32%, and 29% for atezolizumab alone, atezolizumab plus […]

read more

Research supports better integration of patient voice in health technology assessments

A report from Myeloma UK and the National Institute for Health and Care Excellence (NICE) outlines the findings from a study looking at how patient preferences could be more formally incorporated in health technology assessments (HTA). Feedback from a patient and family workshop demonstrated how myeloma impacts the lives of patients in different ways and […]

read more

Data-driven approach to personalised care

One of the greatest strengths of the NHS is its comprehensive datasets of the population from birth to death. A recent paper proposes a new model of cancer care and looks at how data could be examined and used at every stage of the treatment journey, from prevention and diagnosis through to treatment and recovery. […]

read more

Patient reported experience for patients with kidney cancer

In this video interview from Practice Update, Dr Eric Jonasch, board member for the International Kidney Cancer Coalition (IKCC), talks about the results from the recent global survey involving nearly 2,000 kidney cancer patients. Some of the key findings from this survey were; a significant percentage of patients did not know the histology of their […]

read more

ASCO GU 2019: Patient perspectives on cytoreductive nephrectomy after CARMENA

The following survey assessed patient views related to cytoreductive nephrectomy following publication of the results of the CARMENA trial, and were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. The survey found that overall survival should not be overestimated as the most important aim […]

read more

Patient-reported outcomes for atezolizumab plus bevacizumab combination

Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed the atezolizumab plus bevacizumab combination versus sunitinib in metastatic renal cell carcinoma (RCC) patients, were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week. In the IMmotion151 clinical trial, the combination of atezolizumab plus bevacizumab improved progression-free survival […]

read more

Patient-reported outcomes show improved quality of life with the nivolumab-ipilimumab combination

Patient-reported outcomes data from the Phase 3 CheckMate-214 trial of the nivolumab-ipilimumab combination in intermediate- and poor-risk advanced renal cell carcinoma (RCC) patients versus sunitinib show significant benefits in disease-related symptoms and improvements to cancer-related quality of life and well-being.  Patients treated with the nivolumab-ipilimumab combination reported fewer kidney cancer symptoms compared to standard treatment with sunitinib. […]

read more
Showing all 8 results
  TOP